title: Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma.
authors.affiliation: Clinica Ematologica, Centro Trapianti E Terapie Cellulari "Carlo Melzi", DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Dozzo
authors.forename: Francesco
authors.initials: F
authors.lastname: Zaja
authors.forename: Stefano
authors.initials: S
authors.lastname: Volpetti
authors.forename: Alessandra
authors.initials: A
authors.lastname: Sperotto
authors.forename: Alessandro
authors.initials: A
authors.lastname: Magli
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy; D011878:Radiotherapy / Q000379:methods; D011879:Radiotherapy Dosage; D012008:Recurrence; D016879:Salvage Therapy; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin